Young Wendy B. has made a notable move by acquiring 3,789 shares of Rapport Therapeutics, Inc. on October 22, 2026. This acquisition increases her total ownership to 13,289 shares. Such transactions are significant as they highlight investor confidence in the company and its future prospects.

Rapport Therapeutics, Inc. is a company operating within the pharmaceutical preparations industry. The company is incorporated in Delaware and has its business address at 99 High Street, Suite 2100, Boston, MA. It is identified under the Central Index Key (CIK) number 0002012593.

According to the recent SEC filing, Young Wendy B. is a director at Rapport Therapeutics. The filing states, "transaction code P" for purchase, indicating that the shares were acquired rather than sold. The transaction price per share was reported at $26.39.

This acquisition may impact the shareholders and management of Rapport Therapeutics, as it reflects a personal commitment from a director. The filing does not specify any immediate next steps following this transaction.

In this recent transaction, Young Wendy B. acquired 3,789 shares of common stock, bringing her total holdings to 13,289 shares. This acquisition was executed under the transaction code 'P', which specifies that the shares were purchased rather than sold. The shares were purchased at a price of $26.39 each, indicating a significant investment in Rapport Therapeutics.

Young Wendy B. serves as a director at Rapport Therapeutics, a role that underscores her commitment to the company's growth and success. The filing confirms that she does not hold any officer position or ten percent ownership in the company, which may suggest a focus on governance rather than operational control.

The filing also indicates that the transaction was conducted without any involvement in an equity swap, emphasizing the straightforward nature of the share acquisition. The shares are categorized as direct ownership, which means that Young Wendy B. has full control over the shares acquired.

As a director, Young Wendy B.'s investment may signal to other investors and stakeholders her confidence in the company's strategic direction and future potential. However, the filing does not provide additional details regarding any future plans or initiatives that may follow this acquisition.